|drug4084||standard care Wiki||0.50|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.03|
There is one clinical trial.
This study is a randomized, double-blind, multicenter, placebo-controlled trial to evaluate the safety and efficacy of a novel therapeutic agent, Novaferon, in hospitalized adult patients diagnosed with COVID-19. The study is comprised of two cohorts: - Cohort A: This is a blinded safety lead-in comprising two arms. 40 patients will be randomized on a 1:1 basis to receive either Novaferon or matched placebo via a commercial nebulizer, plus Standard of Care (SOC) - Cohort B: This is the main portion of the study, which comprises two arms. Up to 874 patients will be randomized on a 1:1 basis to receive either Novaferon or matched placebo via a commercial nebulizer, plus SOC
Description: Proportion of patients requiring mechanical ventilation or that die (defined as WHO categories 6, 7, or 8)Measure: Rate of clinical deterioration Time: From enrollment to Day 28
Description: Proportion of patients demonstrating clinical improvement (defined as WHO categories 0, 1, 2, or 3)Measure: Rate of recovery Time: From enrollment to Day 28
Description: Rate of non-hospitalized alive patientsMeasure: Hospital discharge rate Time: At Day 28
Description: Mortality rateMeasure: Mortality rate Time: At Day 28
Description: Number of days hospitalizedMeasure: Duration of hospitalization Time: Up to Day 28
Description: Adverse event incidence, type and severityMeasure: Adverse events Time: From first dose to Day 56
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports